Reata Pharmaceuticals, Inc. (RETA)

Trade RETA now with
7/24/2018 9:16:16 PM Reata Pharma Announces Pricing Of Offering Of 3 Mln Shares Of Class A Common Stock At $72.00/shr
7/23/2018 4:40:15 PM Reata Pharmaceuticals Announces Proposed Public Offering Of Class A Common Stock
7/23/2018 6:52:29 AM Reata Announces Results From Two Phase 2 Studies Of Bardoxolone Methyl In Chronic Kidney Disease Patients
6/14/2018 4:31:09 PM Reata Pharmaceuticals Secures $125 Mln Term Loan Facility
6/4/2018 7:35:43 AM Reata Pharma Says Kyowa Hakko Kirin Initiated Ayame, A Phase 3 Trial Of Bardoxolone Methyl For Diabetic Kidney Disease
5/25/2018 5:51:14 AM Will PHOENIX Make RETA Fly?
5/25/2018 3:34:05 AM Reata Reports Presentation Of Positive Interim Data From ADPKD And IgA Nephropathy Cohorts Of Phase 2 PHOENIX Trial
3/22/2018 7:33:20 AM Reata Announces Positive Top-Line Data For Treatment Of PH-ILD With Bardoxolone Methyl From Phase 2 Lariat Trial
3/2/2018 7:34:23 AM Reata Pharma Q4 Net Loss $16.7 Mln Or $0.64/Shr Vs Loss Of $4.1 Mln Or $0.19/Shr Last Year
11/13/2017 7:39:55 AM Reata Pharmaceuticals Q3 Loss $12.3 Mln Or $0.50/shr Vs. Net Loss Of $0.9 Mln Or $0.04/shr Prior Year
10/23/2017 7:37:08 AM Reata Pharma Announces First Patient Enrolled In Part 2 Of MOXIe Study Of Omaveloxolone For Friedreich’s Ataxia
10/20/2017 11:03:51 AM Reata Announces Late-Breaking Presentation Of Primary Results From Phase 2 CARDINAL Study
8/14/2017 7:12:59 AM Reata: FDA Confirms That Use Of MFARS As Primary Endpoint In Part 2 MOXIe Trial Support Approval Of Omaveloxolone In FA